Comparative clinical study to evaluate the efficacy of Vartaku Gutika and Chitrakadi Vati in the management of Grahani Roga (Irritable Bowel Syndrome)

Background: Grahani is a disease of great clinical relevance in modern era because of it’s directly link with improper food habits and stressful lifestyle. Agnimandhya is root cause of Amadosha and it is crucial factor for Grahani and causes Pakwa Apakwa Mala Pravritti. It can be correlated to irritable bowel syndrome. About 15% of the general populations have symptoms that justify diagnosis of IBS. As in the Grahani Agnimandhya is important factor in Samprapti, so it should be treated with Agnivardhan Yogas. Vartaku Gutika which is described in Chakradatta as reseach drug and Chitrakadi Vati mentioned in Charak Samhita for control group. Objectives: To evaluate the effect of Vartaku Gutika and to compare the effect Vartaku Gutika and Chitrakadi Vati in the management of Grahani. Methods: 40 enrolled subjects completed the course of intervention. Randomly they were divided into two groups, group A was given Chitrakadi Vati and group B Vartaku Gutika abd they were adviced 500 mg of tablet two times after food with Ushna Jala, and were adviced to follow Pathya Aahara. Statistical analysis with paired t test, Wilcoxon signed rank test, Mann Whitney test, Mc Nemar test and Chi square test was performed for numerical, ordinal and nominal data respectively. Results: Statistically significant reduction of Lakshana of Grahani in both the group was observed. Overall Vartaku Gutika has more improvement in compared to Chitrakadi Vati. Conclusion: Both Vartaku Gutika and Chitrakadi Vati breaking the pathology of Grahani, but in this study Vartaku Gutika is more effective than compared to Chitrakadi Vati

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

•We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically